Onconetix, Inc. (NASDAQ:ONCO) Short Interest Down 94.6% in October

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 20,300 shares, a drop of 94.6% from the September 30th total of 375,300 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily volume of 676,600 shares, the short-interest ratio is presently 0.0 days.

Onconetix Price Performance

Onconetix stock traded down $0.18 during midday trading on Friday, hitting $3.83. 17,886 shares of the stock were exchanged, compared to its average volume of 336,654. Onconetix has a fifty-two week low of $2.82 and a fifty-two week high of $21.40. The stock’s 50-day simple moving average is $5.11 and its 200 day simple moving average is $5.70.

Onconetix (NASDAQ:ONCO) last announced its earnings results on Thursday, August 29th. The company reported ($9.20) earnings per share for the quarter. The business had revenue of $0.71 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Onconetix, Inc. (NASDAQ:ONCO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned 1.37% of Onconetix as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 23.89% of the company’s stock.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.